Antihypertensive drugs, hypoglycemic drugs and other outpatient drugs will be included in the medical insurance

[pharmaceutical Station industry trends] hypertension and diabetes are relatively common chronic diseases, especially in many middle-aged and elderly people, which greatly threaten human life and health According to the data released by the International Diabetes Union in 2017, there are 114 million people suffering from diabetes and more than 200 million people suffering from hypertension in China For patients, long-term medication is a large burden, which also leads to many patients' irregular treatment, resulting in the waste of medical resources For example, patients with hypertension can only keep their condition stable if they take antihypertensive drugs scientifically and reasonably according to the doctor's instructions However, some patients will reduce or stop the drugs themselves due to the heavy burden of drug use, resulting in complications of heart, brain, kidney and other organs, and even lead to the rupture of heart and brain blood vessels, endangering life It is understood that the complications of these diseases are more serious than hypertension itself If it can reduce the economic burden of patients' medication and make patients use drugs, complications can be well prevented For the patients with diabetes, clinical data shows that about 10 years after the onset of diabetes, 30% - 40% of the patients will have at least one complication At that time, drug treatment is also very difficult, and insulin treatment is needed if the disease is serious, which is not a small burden   On May 13, the state health insurance bureau, together with the Ministry of finance, issued the notice on doing well the basic medical insurance work for urban and rural residents in 2019, which clearly mentioned that it is necessary to establish and improve the overall planning and payment mechanism of medical insurance outpatient expenses for urban and rural residents, focus on protecting the frequently occurring and chronic diseases with heavy burden on the masses, and include the outpatient drugs such as hypertension and diabetes into the medical insurance reimbursement The specific scheme is as follows: Line development According to the proportion of reimbursement previously mentioned in the industry, 50% of outpatient drugs for patients with chronic diseases such as hypertension and diabetes will be reimbursed this year, which also means that the cost burden of drugs for patients with hypertension and diabetes can be reduced by at least half According to the industry, the inclusion of outpatient drugs for chronic diseases such as hypertension and diabetes into the medical insurance can greatly reduce the burden of drug use for patients, and on the other hand, prevent the situation of "drug withdrawal and cash out" The author found that in fact, some regions planned to include outpatient drugs such as hypertension and diabetes into the medical insurance reimbursement as early as this year For example, on March 26, 2019, at the provincial medical security work and meeting of "taking on the responsibilities and implementing the responsibilities", it was mentioned that "outpatient drugs for chronic diseases such as hypertension and diabetes should be included in medical insurance reimbursement" For example, in recent years, the level of medical insurance in Meizhou city has been continuously improved The reimbursement rate of employees with diabetes, hypertension and other specific diseases reached 75%, and that of urban and rural residents with diabetes, hypertension and other specific diseases reached 70% Among them, the annual reimbursement limit of outpatient service for specific diseases of medical insurance for employees with diabetes and hypertension was increased to 6000 yuan and 5000 yuan respectively The annual reimbursement limit of outpatient service for specific diseases of medical insurance for urban and rural residents with diabetes and hypertension was increased to 5000 yuan and 4000 yuan respectively In addition, according to the industry, the second batch of "4 + 7" product catalog in 2019 has been on the agenda and will be released soon Among them, antihypertensive drugs, hypoglycemic drugs and other drugs are the most important It can be seen that with the implementation of the second batch of "4 + 7" centralized procurement, antihypertensive drugs, hypoglycemic drugs and other drugs will usher in another round of big price cuts.